Opticrom Aqueous (Sodium Cromoglicate)

Sodium cromoglicate binds to mast cell membranes in the conjunctiva and inhibits calcium‑dependent degranulation. By blocking the release of histamine, leukotrienes and prostaglandins, it reduces the allergic inflammatory response, thereby relieving ocular symptoms associated with allergy.

The dosing regimen for Opticrom Aqueous is determined by the prescribing clinician based on the severity of the allergic condition, patient age and response to therapy. Typical instructions involve one to two drops per eye at the recommended frequency, but the exact schedule should follow the prescriber’s order.

Safety data for sodium cromoglicate ophthalmic use in pregnancy or lactation are limited. Clinicians should weigh the potential benefits against any unknown risks and consider alternative treatments if appropriate. Pregnant or nursing patients should discuss use with their healthcare provider.

To request Opticrom Aqueous, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Opticrom Aqueous belongs to the mast cell stabilizer class, which prevents mediator release, whereas many eye allergy drops are antihistamines that block histamine receptors after release. Mast cell stabilizers can provide longer‑term control of inflammation, while antihistamines often give rapid symptom relief. The choice depends on clinical needs and physician preference.

The product should be stored at temperatures below 25 °C, protected from light and moisture, and kept in its original container. Do not freeze the solution. Once opened, follow the label’s recommended period‑after‑opening (PAO) and discard any remaining drops if contamination is suspected.

Opticrom Aqueous is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and instill the prescribed number of drops. The eye should be closed gently for a few seconds to allow absorption, and contact lenses should be removed before administration.

Serious adverse events are rare but may include allergic contact dermatitis of the eyelid, severe eye pain, sudden loss of visual acuity, corneal ulceration or anaphylaxis. Patients should seek immediate medical attention if they experience any of these symptoms after using the drops.

Opticrom Aqueous should be avoided in individuals with known hypersensitivity to sodium cromoglicate or any formulation excipients. It is also contraindicated in eyes with active infection, severe corneal disease, or when the patient is unable to follow proper administration techniques.